Glaucoma and allergies: 'should I get rid of my cat?'

This question was posed by an elderly patient with severe glaucoma who recently adopted an adorable kitten. To my cat-loving patient's dismay, the headline of an article in The Telegraph admonished: ‘why owning a cat could lead to blindness’; while another online commentary advised: ‘keep your dog, get rid of your cat’. In view of her advanced glaucoma, should her kitty make way for a little pooch? This uproar can be traced to a recent study by Tseng et al.1 In a retrospective cross-sectional study of 1652 participants in the National Health and Nutrition Examination Survey (NHANES), the authors analysed the association between IgE levels for a panel of common indoor allergens and glaucoma. Weighted estimates were calculated based on the multistage NHANES sampling design for a weighted total of 83 308 318 participants. It was concluded that sensitisation to the cat and cockroach antigens were associated with increased...
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Public health, Angle, Intraocular pressure, Optic nerve, Vision, Neurology, Glaucoma, Epidemiology Editorials Source Type: research

Related Links:

Boosting the sensitivity of in vitroβ-lactam allergy diagnostic tests. Chem Commun (Camb). 2020 Oct 14;56(80):11973-11976 Authors: Peña-Mendizabal E, Morais S, Maquieira Á Abstract The synthesis of structurally new haptens and the development of suitable antigens are essential for boosting the sensitivity of drug allergy diagnostic testing. Unprecedented structural antigens for benzylpenicillin and amoxicillin are characterised and evaluated in a cohort of 70 subjects with a turnkey solution based on consumer electronics. PMID: 33033809 [PubMed - in process]
Source: Chemical Communications - Category: Chemistry Authors: Tags: Chem Commun (Camb) Source Type: research
Publication date: Available online 9 October 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Manuel Jorge Rial, Marcela Valverde, Victoria del Pozo, Francisco Javier González-Barcala, Carlos Martínez-Rivera, Xavier Muñoz, José María Olaguibel, Vicente Plaza, Elena Curto, Santiago Quirce, Pilar Barranco, Javier Domínguez-Ortega, Joaquin Mullol, César Picado, Antonio Valero, Irina Bobolea, Ebymar Arismendi, Paula Ribó, Joaquín Sastre
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: January 2021Source: Biomedical Signal Processing and Control, Volume 63Author(s): Sumaiya Pathan, Preetham Kumar, Radhika M. Pai, Sulatha V. Bhandary
Source: Biomedical Signal Processing and Control - Category: Biomedical Science Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
[Image from University of Michigan]An Allergan-developed gelatin-based stent is showing potential to treat glaucoma in a quicker and safer environment, according to new research from the University of Michigan. Glaucoma is a disease that damages the eye’s optic nerve and can cause vision loss and blindness. Medicines in the form of eyedrops or pills can be used to treat glaucoma. Another option is laser trabeculoplasty which helps drain fluid from the eye. Conventional surgery also creates a new opening in the eye for fluid to leave. Both surgical options are invasive and prone to complications. With the amount of gl...
Source: Mass Device - Category: Medical Devices Authors: Tags: Stents Surgical Allergan Inc. Glaucoma MedTech Source Type: news
CONCLUSIONS: Although the only trial we included in this review found less visual field loss in the brimonidine-treated group, the evidence was of such low certainty that we can draw no conclusions from this finding. Further clinical research is needed to determine whether neuroprotective agents may be beneficial for individuals with OAG. Such research should focus on outcomes important to patients, such as preservation of vision, and how these outcomes relate to cell death and optic nerve damage. As OAG is a chronic, progressive disease with variability in symptoms, RCTs designed to measure the effectiveness of neuro...
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Tags: Cochrane Database Syst Rev Source Type: research
Allergan (NYSE: AGN) said today it inked a deal to buy drug-eluting ophthalmological implant maker ForSight Vision5 for $95 million up front, with a possible milestone payment for launching its drug-eluting device. Pharmaceutical giant Allergan said the device, known as the Helios ring, is designed for extended drug delivery and for reducing intraocular pressure in glaucoma patients. The Helios is designed to rest on the surface of the eye under the eyelids to release bimatoprost over multiple months to lower IOP in glaucoma and ocular hypertensive patients, Allergan said. “The acquisition of ForSight and its oc...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Mergers & Acquisitions Optical/Ophthalmic Allergan Inc. ForSight Vision Source Type: news
By JOHN HALAMKA In my blog posts, I speak from the heart without a specific political or economic motivation. Although I’ve not written about highly controversial subjects such as religion, gun control, or reproductive policy, some of the topics in my posts can be polarizing.   Such as was the case with MACRA. Some agreed with my initial analysis that clinicians will have a hard time translating complex MACRA payment processes into altered clinical behavior.   Others felt I was overharsh, negative and inappropriate.  It’s never my intent to criticize people, instead I want encourage dialog about ...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Uncategorized John Halamaka MACRA Source Type: blogs
In my blog posts, I speak from the heart without a specific political or economic motivation.   Although I’ve not written about highly controversial subjects such as religion, gun control, or reproductive policy, some of the topics in my posts can be polarizing.   Such as was the case with MACRA.   Some agreed with my initial analysis that clinicians will have a hard time translating complex MACRA payment processes into altered clinical behavior.   Others felt I was overharsh, negative and inappropriate.    It’s never my intent to criticize people, instead I want encourage dialog a...
Source: Life as a Healthcare CIO - Category: Information Technology Source Type: blogs
Authors: Doucette LP, Walter MA Abstract Prostaglandins are small pro-inflammatory molecules derived from arachidonic acid that play roles in a multitude of biological processes including, but not limited to, inflammation, pain modulation, allergies, and bone formation. Prostaglandin analogues are the front-line medications for the treatment of glaucoma, a condition resulting in blindness due to the death of retinal ganglion cells. These drugs act by lowering intraocular pressure (IOP), a major risk factor for glaucoma. The currently used prostaglandin analogues (latanoprost, bimatoprost, tafluprost, and travoprost...
Source: Ophthalmic Genetics - Category: Opthalmology Tags: Ophthalmic Genet Source Type: research
More News: Allergy | Allergy & Immunology | Blindness | Brain | Epidemiology | Glaucoma | Health | International Medicine & Public Health | Neurology | Nutrition | Opthalmology | Study